{"nctId":"NCT01576341","briefTitle":"HX575 Epoetin Alfa Subcutaneously (s.c.) in Chronic Kidney Disease (CKD)","startDateStruct":{"date":"2012-04"},"conditions":["Chronic Kidney Disease"],"count":417,"armGroups":[{"label":"HX575 epoetin alfa (Sandoz)","type":"EXPERIMENTAL","interventionNames":["Drug: HX575 epoetin alfa (Sandoz)"]}],"interventions":[{"name":"HX575 epoetin alfa (Sandoz)","otherNames":["Binocrit®, Epoetin alfa HEXAL®, Novicrit®, Abseamed®"]}],"eligibilityModule":{"eligibilityCriteria":"Main Inclusion Criteria:\n\n* Adult male and female patients w or w/o dialysis treatment\n* Stable i.v. or s.c. maintenance therapy with an EU-approved ESA treatment or ESA naïve.\n* Adequate iron substitution\n\nMain Exclusion Criteria:\n\n* History of Pure Red Cell Aplasia (PRCA) or anti-erythropoietin (EPO) antibodies\n* Contraindications for ESA therapy\n* Serum albumin \\< 3.0 g/dL\n* Immunocompromized patients (immunosuppressive treatment, chemotherapy)\n* Hepatitis C infection on an active treatment or hepatitis B or human immunodeficiency virus (HIV) infection\n* Systemic lupus erythematosus\n* Symptomatic congestive heart failure, Unstable angina pectoris, or myocardial infarction within 6 months\n* History of malignancy of any organ system within the last 5 years\n* History of use of any non-EU approved ESA","healthyVolunteers":false,"sex":"ALL","minimumAge":"18 Years","stdAges":["ADULT","OLDER_ADULT"]},"locations":{"multicenter":true},"periods":[],"outcomeMeasures":[{"type":"PRIMARY","title":"Anti-Erythropoietin (EPO) Antibodies","description":"The incidence of antibody formation against epoetin in Radio-immuno-precipitation (RIP) assay","paramType":"NUMBER","dispersionType":"95% Confidence Interval","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1.7","spread":null}]}]}]},{"type":"SECONDARY","title":"Hemoglobin Level and Change From Baseline Period at Visit 16 (End of Study)","description":"Actual values of hemoglobin levels at end of study visit and change from Baseline Period (Week -4 to Week -1)","paramType":"MEAN","dispersionType":"Standard Deviation","classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"10.81","spread":"1.336"},{"groupId":"OG001","value":"10.86","spread":"1.060"},{"groupId":"OG002","value":"10.83","spread":"1.226"}]}]},{"categories":[{"measurements":[{"groupId":"OG000","value":"1.61","spread":"1.601"},{"groupId":"OG001","value":"0.22","spread":"1.223"},{"groupId":"OG002","value":"1.02","spread":"1.606"}]}]}]}],"adverseEventsModule":{"adverseEventsSummary":{"seriousAny":{"events":103,"n":416},"commonTop":["Hypertension","Renal failure chronic","Hyperkalaemia","Nasopharyngitis","Pneumonia"]}}}